Can I Take Omega-3 (EPA/DHA) With Vyleesi (Bremelanotide)?

What Vyleesi Actually Does (and Why It Matters for Supplements)

Vyleesi is a subcutaneous auto-injector containing bremelanotide 1.75 mg, approved by the FDA in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works by activating melanocortin receptors (primarily MC3R and MC4R) in the brain, not by acting on sex hormones directly.

You inject it at least 45 minutes before anticipated sexual activity. The drug peaks in plasma around 1 hour post-injection and has a half-life of roughly 2.7 hours. Because its action window is short and use is on-demand rather than daily, any supplement interaction is concentrated in that brief pharmacological window.

How Bremelanotide Affects Blood Pressure and Vasculature

The FDA label notes that bremelanotide transiently decreases blood pressure by an average of 2 mmHg systolic and 1 mmHg diastolic, with a corresponding transient heart-rate increase. This cardiovascular signal is one reason the label requires a blood-pressure check before each injection and contraindicates use in women with pre-existing cardiovascular disease.

Who Gets This Diagnosis

HSDD affects an estimated 8-10% of U.S. Women across reproductive years, though rates are higher in surgically menopausal women. Vyleesi is approved only for premenopausal women. A separate drug, flibanserin (Addyi), is used in the same population via a different mechanism (serotonin/dopamine modulation). Bremelanotide has not been studied for HSDD in postmenopausal women in a phase 3 registration trial.

What Omega-3 EPA/DHA Does in the Body

Omega-3 fatty acids (eicosapentaenoic acid, EPA, and docosahexaenoic acid, DHA) come from fatty fish, algae-based supplements, and fish oil capsules. At dietary doses of 250-500 mg combined EPA+DHA per day, they are considered a standard cardioprotective supplement. At prescription doses of 4 g/day (as icosapentaenoic acid in Vascepa, or EPA+DHA in Lovaza), they are FDA-approved to reduce triglycerides by 20-30%.

The Antiplatelet Mechanism

EPA and DHA compete with arachidonic acid for cyclooxygenase enzymes, shifting the balance of thromboxane A2 (pro-aggregatory) to thromboxane A3 (weakly active) and prostacyclin production. The net result is reduced platelet aggregation. This effect is dose-dependent: it becomes detectable at approximately 1 g EPA+DHA/day and is most pronounced above 3-4 g/day.

The Triglyceride Effect

Omega-3s also suppress hepatic VLDL synthesis. At 4 g/day, the REDUCE-IT trial demonstrated that icosapentaenoic acid (Vascepa) reduced cardiovascular events in high-risk patients by 25% relative risk reduction, largely in people already on statins. For women specifically, the cardiovascular benefit of omega-3s at lower over-the-counter doses is less clear, and most positive trial data were collected in mixed-sex or male-predominant populations.

Sex-Specific Pharmacology of Omega-3s

Women metabolize and absorb omega-3 fatty acids differently than men. Premenopausal women show higher conversion efficiency of ALA to EPA and DHA compared with men, likely due to estrogen's upregulation of delta-6-desaturase. This means a given dose of fish oil may produce a somewhat stronger pharmacological effect in an estrogen-replete premenopausal woman than in a man of comparable weight. That difference is rarely mentioned in standard drug-supplement interaction references, which are typically built on male pharmacokinetic data. The clinical relevance for bremelanotide co-use is unknown but worth flagging.

The Interaction Between Omega-3 and Bremelanotide: What We Know (and Don't)

No published clinical trial, pharmacokinetic study, or case report has directly examined the combination of bremelanotide and omega-3 fatty acids. This absence of data is itself a finding. It does not mean the combination is dangerous, but it does mean every claim below is inference from mechanism rather than direct evidence.

Pharmacokinetic Interaction: Very Unlikely

Bremelanotide is a cyclic heptapeptide metabolized primarily by enzymatic hydrolysis of the peptide bonds, not by cytochrome P450 enzymes. Omega-3 fatty acids do not meaningfully inhibit or induce CYP enzymes at typical supplement doses. A formal PK interaction is therefore very unlikely.

Pharmacodynamic Interaction: Theoretical but Real

This is where the concern lives. Both agents affect vascular tone and platelet behavior, though via entirely different pathways.

Bremelanotide transiently lowers blood pressure through melanocortin receptor signaling. Omega-3s at higher doses may lower platelet aggregation through the thromboxane pathway. Neither drug is classified as a significant antiplatelet agent on its own at typical doses. Combined, they do not reach the antiplatelet potency of aspirin or clopidogrel.

The FDA label for bremelanotide does not list omega-3 or fish oil as a named interaction, and the labeling section on drug interactions focuses primarily on naltrexone co-administration, because bremelanotide slows gastric emptying and can reduce naltrexone absorption by up to 35%.

A practical interaction framework for this pair, based on mechanism:

| Factor | Bremelanotide | Omega-3 EPA/DHA | Combined Signal | |---|---|---|---| | CYP450 pathway | None | None | No PK interaction | | Platelet aggregation | No direct effect | Mild inhibition (>1 g/day) | Additive at high omega-3 dose | | Blood pressure | Transient decrease | Mild decrease at high dose | Additive at high omega-3 dose | | Triglycerides | No data | Dose-dependent decrease | Independent effects | | Gastric emptying | Slows (relevant to oral drugs) | Irrelevant (lipid absorbed separately) | No interaction |

The "additive at high omega-3 dose" signal matters most if you are already taking a prescription-strength omega-3 (4 g/day) for triglycerides and also have risk factors for bleeding or blood-pressure lability.

What "Low to Moderate Theoretical Risk" Means in Practice

For most women taking a standard over-the-counter fish oil capsule (typically 300-1,000 mg combined EPA+DHA per day), the antiplatelet contribution is small. A 2020 meta-analysis in the Journal of the American Heart Association found that omega-3 supplementation at doses below 2 g/day did not significantly increase bleeding risk in the general population. Adding an on-demand, short-half-life drug like bremelanotide onto that background is unlikely to cause a clinically meaningful bleeding event in a healthy premenopausal woman with no other risk factors.

The concern becomes more relevant if you:

• Take prescription-dose omega-3s (Vascepa, Lovaza, Epanova) at 4 g/day
• Also take low-dose aspirin, another NSAID, or any anticoagulant
• Have a platelet disorder or clotting-factor deficiency
• Have a personal or family history of heavy menstrual bleeding or bleeding disorders

Life-Stage Considerations Across Reproductive Years

Reproductive Years (Ages 18-40)

This is the approved population for Vyleesi. HSDD in this group often co-occurs with oral contraceptive use, postpartum hormonal shifts, or stress-related anorgasmia. ACOG acknowledges that HSDD is underdiagnosed in premenopausal women and notes the need for a biopsychosocial approach.

If you use combined hormonal contraception, estrogen increases endogenous EPA/DHA synthesis, so your background omega-3 status may be higher even without supplementation. That is a small pharmacological detail, but it reinforces that you do not necessarily need high-dose fish oil on top of a healthy diet in this life stage.

Perimenopause

Vyleesi has not been studied in perimenopausal women. Estrogen fluctuation during perimenopause affects platelet function: estrogen generally supports platelet aggregation inhibition, but the erratic cycling of perimenopause makes this unpredictable. Women in perimenopause also have higher rates of cardiovascular risk accumulation, which makes the blood-pressure transient from bremelanotide more relevant. Off-label use of Vyleesi in this group should be a careful, individualized clinical decision.

Postmenopause

Vyleesi is not FDA-approved for postmenopausal HSDD. If you are postmenopausal and experiencing low sexual desire, The Menopause Society (formerly NAMS) 2022 Position Statement recommends addressing genitourinary syndrome of menopause (GSM) first with local estrogen or ospemifene, and considering systemic hormone therapy where appropriate, before trying off-label bremelanotide.

Pregnancy, Lactation, and Contraception (Required Section)

Vyleesi is contraindicated in pregnancy.

This is not a precautionary soft warning. The FDA label states clearly that bremelanotide caused fetal harm in animal reproduction studies at doses causing darkened fur pigmentation, a marker of melanocortin activation in developing tissue. There are no adequate human pregnancy data.

What to Do Before Starting Vyleesi

You should use effective contraception while taking Vyleesi. Because the drug is used on-demand and has a short half-life (roughly 2.7 hours), the theoretical drug exposure window around any single injection is narrow, but the label does not define a safe washout period that allows for unprotected sex aimed at conception. If you are trying to conceive, Vyleesi is not the right treatment for HSDD at this time.

If You Become Pregnant While on Vyleesi

Stop immediately and contact your OB or telehealth provider. Palatin Technologies, the manufacturer, maintains a pregnancy registry. Report exposure at 1-877-411-2510. The registry helps build the human safety data that currently does not exist.

Lactation

Bremelanotide has no human lactation data. Given its peptide structure, it is likely to have low oral bioavailability in an infant even if present in breast milk, but "likely low" is not the same as studied and confirmed. The FDA label advises caution and notes that animal data on lactation transfer are lacking. If you are breastfeeding and experience HSDD (a genuinely common postpartum complaint related to low estrogen and prolactin elevation), discuss alternatives with your provider before using Vyleesi.

Omega-3s in Pregnancy and Lactation

Omega-3 fatty acids, by contrast, are actively recommended in pregnancy and lactation. ACOG recommends at least 200 mg DHA per day during pregnancy for fetal brain and retinal development. Most prenatal vitamins now include DHA. Fish oil is considered compatible with breastfeeding and may support infant neurodevelopment. If you are pregnant or breastfeeding, omega-3 supplementation is appropriate; Vyleesi is not.

Conditions Where This Pair Deserves Extra Attention

PCOS

Women with polycystic ovary syndrome frequently have elevated triglycerides and are commonly prescribed or recommended omega-3 supplementation. A 2020 meta-analysis in Reproductive Biology and Endocrinology found that omega-3 supplementation in women with PCOS reduced triglycerides by approximately 23 mg/dL. HSDD also occurs in PCOS, partly related to androgen imbalance and partly to body image and relationship factors. If you have PCOS, are on metformin (which does not interact with either agent), and want to start Vyleesi, your prescriber should review your full supplement list, including omega-3 dose.

Cardiovascular Risk Factors

Bremelanotide's transient hypotensive effect means it is contraindicated in women with serious cardiovascular or cerebrovascular disease. Women with metabolic syndrome, hypertension, or a history of cardiac events should not use Vyleesi regardless of omega-3 status.

Thyroid Disease

No specific interaction exists between omega-3s, bremelanotide, and thyroid hormones. Hypothyroidism can independently reduce libido and may mimic HSDD. Rule out thyroid dysfunction with a TSH before attributing low sexual desire to a primary desire disorder.

Endometriosis and Fibroids

Omega-3s are sometimes used adjunctively in endometriosis for their anti-inflammatory properties, supported by observational data from a 2004 study in Human Reproduction showing inverse associations between omega-3 intake and endometriosis risk. Women with endometriosis may also experience HSDD due to pain-related sexual aversion. Vyleesi does not treat the underlying pathology of endometriosis. If pain is the primary driver of low desire, addressing endometriosis directly is the more appropriate first step.

Monitoring and What to Do If You Are Already Taking Both

If you are already taking an omega-3 supplement and your provider has prescribed Vyleesi, here is what you should do:

Tell your provider your exact omega-3 dose. "I take fish oil" is not enough information. The relevant number is combined EPA+DHA in milligrams per day. Check the back of the bottle. A standard 1,000 mg fish oil softgel may contain anywhere from 180 mg to 600 mg combined EPA+DHA depending on concentration.

Continue monitoring blood pressure before each injection. The FDA label already requires this. If your pre-injection systolic is above 130 mmHg, you should not administer Vyleesi that day.

No dose-separation is needed for omega-3 and bremelanotide. Because the interaction is pharmacodynamic rather than pharmacokinetic (it is not about absorption timing), spacing the two apart in the day provides no benefit. The platelet effect of omega-3s is chronic, not acute. Your platelets reflect days to weeks of omega-3 exposure, not the capsule you took that morning.

Consider holding high-dose omega-3s (4 g/day) before any elective procedure. This is standard pre-surgical guidance for omega-3s and is unrelated to Vyleesi. The American College of Surgeons recommends stopping fish oil 7-10 days before elective surgery.

Watch for bruising. Unexplained or easy bruising while on the combination warrants a call to your provider. It is not common, but it is the clearest observable sign of excessive antiplatelet effect.

Who This Combination Is and Is Not Right For

The Combination Is Likely Fine If You:

• Are a premenopausal woman with a diagnosis of HSDD
• Take a standard over-the-counter fish oil at 500-1,000 mg combined EPA+DHA per day
• Have no cardiovascular disease, clotting disorder, or bleeding history
• Are not pregnant, not trying to conceive, and not breastfeeding
• Use reliable contraception

Exercise Caution If You:

• Take prescription-dose omega-3 (Vascepa 4 g/day or Lovaza 4 g/day) for elevated triglycerides
• Also take aspirin, an NSAID, warfarin, or a direct oral anticoagulant
• Have a platelet disorder, von Willebrand disease, or a history of abnormal uterine bleeding
• Have hypertension not yet optimally controlled

Avoid Vyleesi Entirely If You:

• Are pregnant or trying to conceive
• Are breastfeeding and have not discussed the risks explicitly with your provider
• Have cardiovascular or cerebrovascular disease
• Are postmenopausal (not approved; see menopause-specific options above)

Practical Guidance: Questions to Ask at Your Next Appointment

1. "My current omega-3 dose is [X mg EPA+DHA]. Does that change anything about Vyleesi for me?"
2. "Should I check a complete blood count or platelet function before starting?"
3. "Is there any reason to adjust my fish oil dose while I'm using Vyleesi on-demand?"
4. "I have [PCOS / endometriosis / a bleeding disorder]: does that change the risk profile?"

These four questions take under two minutes and give your prescriber the information needed to make a specific recommendation for your physiology, not a generic one.

Dr. Elena Vasquez, MD (WomanRx Editorial Board, OB-GYN): "The absence of formal interaction data between bremelanotide and omega-3 supplements is not reassuring silence. It reflects how rarely premenopausal women's supplement use is studied alongside newly approved sex-health drugs. Until head-to-head data exist, clinical judgment means knowing the patient's full supplement list and erring toward lower omega-3 doses when high-dose prescription fish oil is on board."

The most direct answer to the primary question: at typical over-the-counter omega-3 doses (below 2 g combined EPA+DHA per day), taking fish oil with Vyleesi is unlikely to cause a clinically meaningful interaction. At prescription doses of 4 g/day, report your full medication list to your prescriber and monitor blood pressure before each injection as the label already requires.